TABLE 2.
Genetic polymorphisms in the 34 patients analyzed in the study of tenofovir and emtricitabine concentrations in the ANRS 134-COPHAR 3 trial
| Polymorphism | Caucasian |
Africanb |
||
|---|---|---|---|---|
| No. (%) | P a | No. (%) | P a | |
| ABCC2 rs717620 CC/CT | 14 (60)/9 (30) | 0.49 | 7 (70)/3 (30) | 0.76 |
| ABCC4 rs1751034 AA/AG/GG | 16 (70)/7 (30)/0 (0) | 0.64 | 3 (30)/5 (50)/2 (20) | 0.97 |
| ABCB1 rs1045642 CC/CT/TT | 6 (26)/11 (48)/6 (26) | 0.83 | 6 (60) /3 (30)/1 (10) | 0.53 |
a
P, Hardy-Weinberg equilibrium P value.
b
One of the 11 African patients had no genotype information available.